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Abstract
Fibronectin (FN) is a ubiquitous extracellular matrix (ECM) glycoprotein that plays vital roles during tissue repair.
The plasma form of FN circulates in the blood, and upon tissue injury, is incorporated into fibrin clots to exert
effects on platelet function and to mediate hemostasis. Cellular FN is then synthesized and assembled by cells as
they migrate into the clot to reconstitute damaged tissue. The assembly of FN into a complex three-dimensional
matrix during physiological repair plays a key role not only as a structural scaffold, but also as a regulator of cell
function during this stage of tissue repair. FN fibrillogenesis is a complex, stepwise process that is strictly regulated
by a multitude of factors. During fibrosis, there is excessive deposition of ECM, of which FN is one of the major
components. Aberrant FN-matrix assembly is a major contributing factor to the switch from normal tissue repair to
misregulated fibrosis. Understanding the mechanisms involved in FN assembly and how these interplay with
cellular, fibrotic and immune responses may reveal targets for the future development of therapies to regulate
aberrant tissue-repair processes.
Introduction
Fibronectin (FN) is a ubiquitous and essential component
of the extracellular matrix (ECM). It functions both as a
regulator of cellular processes and an important scaffold-
ing protein to maintain and direct tissue organization
and ECM composition.
During tissue repair, the body acts in a series of tightly
regulated steps to rapidly reconstitute damaged tissue:
the formation of a fibrin clot acts as the platform for
granulation tissue assembly, with subsequent contraction
and remodeling of the ECM to reform normal tissue
[1,2]. Different forms of FN play differential and tempo-
rally discrete roles during tissue repair. Plasma FN and
cellular FN possess distinct structures and rates of assem-
bly into three-dimensional matrices.
In this paper, we discuss the differences in the structure
of plasma and cellular FN, and their roles during the dif-
ferent stages of tissue repair. We summarize current the-
ories of how FN is assembled into a three-dimensional
matrix, and how this process is regulated. Understanding
this complex matrix-assembly process may highlight
potential targets for therapeutic advancement in the
treatment of aberrant tissue-repair conditions.
Structure of fibronectin isoforms
FN is a multi-domain glycoprotein composed of an array
of multiple repeated modular structures: twelve FN type I
repeats (FNI), two FN type II repeats (FNII), fifteen con-
stitutively expressed and two alternatively spliced (in this
paper, referred to as EIIIA and EIIIB) FN type III (FNIII)
repeats, and a non-homologous variable (V) or type III
connecting segment (IIICS) region. The multimodular
structure and intermodular regions allow flexibility of the
FN molecule, which is involved in regulating its function
[3-8]. These modules are organized into functional
domains, including the N-terminal 70-kDa domain
(FNI1-9), the 120-kDa central binding domain (CBD;
FNIII1-12) and the heparin-binding domain HepII
(FNIII12-14). The specific domains of FN can interact
with multiple binding partners, including other ECM
components and cell-surface receptors [9]. FN is secreted
as a dimer maintained by two disulfide S-S bonds at its
C-terminus [7,10-12] (Figure 1).
Plasma fibronectin
Plasma FN is synthesized by hepatocytes and secreted into
the blood plasma, where it circulates at 300-400 μg/ml
[13] in a soluble, compact, inactive form. In soluble plasma
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and EIIIA modules are absent [14-16]. Only very low levels
(1.3-1.4 μg/ml) of FN possessing the EIIIA and/or EIIIB
modules (cellular FN) have been reported to circulate in
the blood plasma [17], but blood plasma levels have been
shown to increase after major trauma resulting in vascular
tissue damage, after inflammation, and in diseases such as
atherosclerosis, ischaemic heart disease and stroke [18-21].
Cellular fibronectin
Cellular FN is synthesized by many cell types, including
fibroblasts, endothelial cells, chondrocytes, synovial cells
and myocytes [22]. Cellular FN is a mixture of FN iso-
forms. The alternative splicing of EIIIB and EIIIA and
more complex splicing of the V or IIICS domain during
transcription of cellular FN allows different isoforms of
FN to be expressed in a tissue-dependent, temporally
regulated, and cell-type-specific manner [15,23-26]. In
humans, 20 potential FN isoforms can be generated
[27]. Increased expression of the EIIIA+ and EIIIB+ iso-
forms of FN are associated with areas of physiological
or pathological tissue remodeling, including wound heal-
ing and tissue repair. The observed isoforms of FN, and
their association with physiological or pathological con-
ditions, are outlined in Table 1. These isoforms modu-
late the properties of the ECM, and affect cellular
processes.
The orientation and rotational interdomain flexibilities
of FNIII modules are known to be affected by neighboring
domains, so the inclusion or exclusion of alternatively
spliced domains may change the global conformation of
FN, affecting the presentation of FNIII loop structures and
binding sequences to modulate FN-cell signaling and FN-
FN interactions during matrix assembly [9,28-33]. The
structural composition of the different FN isoforms are
important, as they play distinct roles in early and late
wound-healing events [16].
Fibronectin in early wound-healing responses
Plasma FN is a major component of the fibrin clot. Mul-
tiple mechanisms allow FN to be incorporated into the
fibrin matrix. FN can interact via non-covalent interac-
tions with fibrin via its FNI1-5 and FNI10-12 domains [34].
FN is also covalently crosslinked to fibrin by activation of
the blood coagulation cascade involving activated Factor
XIIIa (plasma transglutaminase or coagulation factor
XIII) [2,14,16,35]. This crosslinks FN via glutamine resi-
dues within its N-terminus [36] to the fibrin a chains via
ε-(g-glutamyl) lysine cross links [37]. Furthermore,
plasma FN can also be bound and then assembled into a
high-molecular-weight multimeric matrix on the platelet
surface. Platelet activation by thrombin induces increased
cell-surface expression of the major platelet integrin
aIIbb3, which binds and assembles FN via a fibrin-inde-
pendent mechanism [38-44]. Platelets also express a
l o w e rn u m b e ro fa5b1a n davb3 receptors on their sur-
face, which mediate platelet adhesion [45]. Aggregated
Figure 1 Fibronectin (FN) and FN fragments. FN is composed of a series of FNI repeats (dark-gray boxes), FNII repeats (circles), conserved FNIII
repeats (light-gray boxes) and alternatively spliced FNIII repeats (EDA).
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pathway [44]. The polymerization of fibrin into a three-
dimensional network has been shown to be essential for
FN assembly, as the g chain of unprocessed fibrinogen
signals via aIIbb3 to inhibit this process [38].
Platelet-producing megakaryocytes endocytose and
pinocytose FN from the plasma, which becomes pack-
aged into the a granules of platelets [46]. This has been
shown to involve the aIIbb3 integrin; mice with a muta-
tion in the gene encoding the fibrinogen g chain (which
prevents fibrinogen interactions with aIIbb3), von Will-
ebrand factor null mice, and fibrinogen null mice show
increased FN levels in their a granules [47-49]. Upon
platelet activation, FN is released from a granules in a
process called degranulation. The FN released from pla-
telets can also assemble on the surface of platelets
Table 1 Cellular fibronectin (FN) isoforms reported during physiological and pathological conditions
FN isoform Characteristics Ref.
Physiological wound
healing
EIIIA Expressed in tubular basement membrane by endothelium in rat model of acute renal failure; involved in
regeneration of proximal tubules
[237]
Increased expression by alveolar septal cells, albeolar macrophages and endothelial cells upon acute hyperoxic lung
injury
[238]
Absence results in abnormal wound healing in EIIIA
-/- mice [90]
Expressed in rat model of liver injury by sinusoidal endothelial cells [98]
EIIIB Increased levels in blood plasma after acute major trauma [18]
Increased expression by chondrocytes in muscularized arteries upon acute hyperoxic lung injury [238]
EIIIA and EIIIB Observed in granulation tissue by 7 days; EIIIB+ levels remain increased even after 14 days; EIIIA+ found around
arterioles in connective tissue adjacent to the wound after 4 days
[95]
Deposited in basement membrane zone of keratectomy wound models of corneal injury in rats [239]
Detected in ulcerated gastric tissue in rat models [240]
EIIIA, EIIIB and V All isoforms upregulated during rat corneal wound healing [241]
Pathological conditions
Fibrosis
EIIIA Idiopathic pulmonary fibrotic fibroblasts isolated from patients express higher levels of EIIIA+FN [201]
Involved in lung fibrogenesis in rat models of pulmonary fibrosis [201]
Highly expressed in mesangium and interstitium in rat glioblastoma multiforme and Habu snake venom models of
renal fibrosis
[202]
Increased expression in acute and chronic cutaneous graft-versus-host disease [200]
Increased in fibrotic periglomerular regions and areas of interstitial fibrosis [26]
Increased expression in human hepatic fibrosis [242]
Can induce the conversion of lipocytes to myofibroblasts; may play a role in hepatic fibrogenesis [98]
EIIIB Increased in obsolescent glomeruli [26]
EIIIA and EIIIB Increased in glomerulosclerotic lesions and fibrous crescents [26]
Tumorigenesis
EIIIA Increased expression in hepatocellular carcinomas [242]
EIIIB Increased expression in interstitium and vascular intima of many primary human tumors including meningioma [243]
Expressed around neovasculature and stroma of many malignant head and neck tumors [244]
Detected around tumor stroma, tumor vasculature and in tissue adjacent to the invasion front of oral squamous cell
carcinomas
[245]
Detected in the stroma, in the cytoplasm of tumor cells and endothelial cells in the neovasculature of head and
neck squamous cell carcinomas
[246]
EIIIA and EIIIB Expressed in tumor blood vessels in mouse model of pancreatic tumorigenesis [247]
Present around the blood vessels of intratumoral microvessels in breast carcinomas. [248]
Other
EIIIA Increased plasma levels in synovial fluid of rheumatoid arthritic joints [249]
EIIIA, EIIIB and V Increased expression in rat model of hypertension, especially of EIIIA+ form after 21 d [250]
To and Midwood Fibrogenesis & Tissue Repair 2011, 4:21
http://www.fibrogenesis.com/content/4/1/21
Page 3 of 17[42,46,50]. FN incorporation into the fibrin matrix is
important for various platelet functions, including adhe-
sion, migration and aggregation (Figure 2) [16,36,38,45,
46,48,49,51-98]. However, in vitro fibrin assembly was
shown to be unaffected by a complete absence of plasma
FN [51]. Furthermore, plasma FN conditional knockout
mice, or mutant mice with reduced plasma FN levels of
50% or 70-80%, were shown to have normal clotting
and bleeding times. Minimal effects on wound healing
in these mice were seen in vivo [17,51,52]. Cellular FN
isoforms possessing the alternatively spliced EIIIA and
EIIIB domains, derived from platelets, are thought to
compensate for the loss of plasma FN in these condi-
tions [51]. Although it has been shown that cellular FN
isoforms are not efficiently incorporated into the fibrin
clots in vitro, it is thought that they may be sufficient to
allow normal wound-healing events in vivo.
The fibrin-FN provisional matrix allows FN to adopt
extended conformations within the fibrin-FN matrix,
which leads to the exposure of cryptic cell binding
domains to facilitate cellular processes (Figure 2) [36].
For example, fibroblast activation by various growth fac-
tors such as platelet-derived growth factor requires spe-
cific sequences within the heparin domain and IIICS
region [99].
Fibronectin in the late wound-healing responses
Endothelial cells and fibroblasts repopulate the wound
and deposit cellular FN, an important and abundant
component of granulation tissue [1,2,66,100]. FN
Figure 2 Functions of plasma and cellular fibronectin (FN) during wound healing. The different forms of FN play distinct roles during the
different stages of wound healing.
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granulation tissue, and forms a dense network around
fibroblasts, which polarize along the FN fibrils, parallel
to the epidermis [66,95]. FN assembly into a three-
dimensional fibrillar network on the cell surface is vital
for establishing and maintaining tissue architecture and
for regulating cellular processes including adhesion
[57-60], spreading [101], proliferation [58,101-103],
migration [99,104-106] and apoptosis [107,108] (Figure
2). The three-dimensional FN structural matrix plays an
important role in regulating both ECM composition
[61,67] and the deposition of other ECM molecules,
including collagen types I and III [61,68-74], fibrinogen
[75], fibrillins 1 and 2 [76-78], fibulin [79], laminin
[61,73,80] and tenascin (TN)-C [81,82]. Reticulin has
also been shown to colocalize with FN fibrils within the
granulation tissue [66]. The FN matrix can also seques-
ter growth factors and associated proteins, including
bone morphogenetic protein-1 [83], vascular endothelial
growth factor (VEGF) [84] and latent transforming
growth factor (TGF)-b binding proteins (LTBP) 1, 3 and
4 [67,85-87] to regulate cell signaling events. While the
FN matrix is continuously assembled, remodeled and
turned over by cells, a more mature and stable ECM
network assembles on this FN-matrix scaffold [61,85,88]
(Figure 2).
FN in the wound site is also vital for regulating the
neovascularisation of granulation tissue during the reso-
lution of tissue injury. Exposure of different ECM protein
conformations in the vascular basement during wound-
ing acts as an important cue to regulate angiogenesis
[55,96]. FN expression, especially of isoforms possessing
the alternatively spliced EIIIA+ and EIIIB+ modules are
highly upregulated around neovessels and capillary
sprouts within the highly vascularized granulation tissue
[95,97,98]. An FN fibrillar network has been shown to be
required for proliferation and migration of human umbi-
lical-vein endothelial cells in a three-dimensional envir-
onment [109], and functions to promote endothelial-cell
survival [24,110] (Figure 2).
Myofibroblast differentiation is dependent on the pre-
sence of both TGF-b and EIIIA+FN and on the dramatic
changes in the mechanical properties of the wound micro-
environment [89,111,112]. Myofibroblasts form specialized
actin-associated fibronexus adhesion complexes, which
function in mechano-transduction to allow transmission
of intracellular actin-generated contractile forces and the
sampling of extracellular tension [111-114]. These specia-
lized adhesion complexes may also function in myofibro-
blast-dependent contracture of the wound, which acts to
‘shorten’ and remodel the collagen-rich matrix, resulting
in closure of the wound and recapitulation of normal
tissue architecture and function.
The data highlighted here indicate distinct and discrete
roles for the two different forms of FN during tissue injury
and repair. Plasma FN and cellular FN are differentially
expressed both temporally and spatially during wound
healing: plasma FN circulates in the blood and functions
during early wound-healing responses, whereas cellular
FN is expressed and assembled locally and functions dur-
ing later wound-healing responses. However, despite this
non-overlapping expression and localization of the FN iso-
forms during wound healing, exogenous plasma FN can
be assembled into pre-existing or newly assembling cellu-
lar FN matrices even if the plasma FN is isolated from a
different species [115-117]. Although plasma FN shows
slower initial kinetics of assembly than cellular FN [12],
these data imply that plasma and cellular FN could poten-
tially perform the same functions. Supporting this hypoth-
esis, conditional plasma FN knockout mice were found to
have normal wound healing and hemostasis [51], suggest-
ing possible compensation by cellular isoforms of FN.
However, in other physiological and pathological pro-
cesses, these isoforms have been shown to be distinct and
unique in their functions; plasma FN was found to be
essential for protecting neuronal and non-neuronal cells
from apoptosis after transient focal cerebral tissue ischae-
mia [51] and after traumatic brain injury [118], as cellular
FN is not expressed in these damaged brain tissues.
Furthermore, EIIIA-FN null mice were shown to have
impaired abnormal skin wound-healing responses with
reduced cell compaction and edematous-like areas within
the granulation tissue and delayed re-epithelialization [90].
These results would suggest that EIIIA+FN plays an
important role in the resolution of late wound-healing
processes. Tan et al. reported that EIIIA-FN null mice on
a different background strain showed no effect on wound
healing, but did show reduced atherosclerosis, suggesting
that cellular isoforms of FN contribute to pathological
conditions [119]. These studies suggest independent roles
for the different isoforms of FN, which cannot always be
compensated for in their absence.
Fibronectin-matrix assembly
There is still much that we do not know about how FN
is assembled or how the rate of deposition is controlled.
Understanding the mechanisms that regulate FN-matrix
assembly will allow us to control this process when it
becomes misregulated.
Plasma FN in solution alone will not polymerize [120]
and will not form a three-dimensional matrix in the
absence of cells [116]. Both plasma and cellular FN are
expressed and secreted in a soluble, compact form, which
is maintained by intramolecular electrostatic interactions
between the FNI1-5, FNIII1-2,F N I I I 2-3 and FNIII12-14
domains [7,10-12] (Figure 3A). In low-salt conditions,
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tron microscopy [6,8], and Förster resonance energy
transfer studies have shown that the arms of soluble FN
overlap each other [121]. FN mutants lacking FNIII12-14
or having this region replaced by the alternatively spliced
FN type III domains A1-A3 from tenascin-C (TN-C), had
lower sedimentation coefficient values, reflecting adop-
tion of a more open conformation and highlighting the
importance of FNIII12-14 in maintaining these intramole-
cular interactions [7].
FN-matrix assembly is a stepwise, cell-mediated pro-
cess [122,123]. The process seems to be rapid, as initial
FN deposits appear at the cell surface within 10 minutes
of plating, and in the conditioned medium within 30
minutes [122]. FN dimerisation is required for FN
assembly, as mutation of C-terminal cysteines results in
the loss of fibrillogenesis [124]. This process is briefly
discussed below, but is discussed in more depth else-
where [125].
Initiation of fibronectin-matrix assembly
Initiation of assembly involves FN binding to cell-surface
receptors (Figure 3A(i, ii). Integrins that bind FN are
summarized in Table 2, although some (for example,
avb1) do not support FN fibrillogenesis. Mice engineered
to be deficient in FN, a5, b1o rav, or to express FN-
RGE (FN
RGE/RGE; the RGD integrin-binding sequence of
FNIII10 is mutated to RGE) all exhibit embryonic lethal-
ity, highlighting the importance of FN fibrillogenesis and
the FN fibrillar matrix during development [126-128].
FN is thought to bind first to the cell surface via FNI1-5
within the 70-kDa N-terminal domain of FN (hereafter
referred to as ‘70-kDa’; Figure 3Ai) [58,124,129-135].
Initiation of FN-matrix assembly occurs at focal contacts,
which are initial sites of ECM contact on the cell periph-
ery, which are rich in paxillin, vinculin, phosphotyrosines,
and b1a n db3 integrins [136,137]. The receptor(s) for
70-kDa have not yet been clearly elucidated. Interactions
with avb3 integrins have been shown to interact with the
novel Gly-Asn-Gly-Arg-Gly (GNGRG) motif in FNI1-5
[126,138]. However, recent work has shown that muta-
tion of the two GNGRG sequences within 70-kDa has no
effect on the binding of 70-kDa or FN to adherent cells
or on the ability of 70-kDa to compete for FN binding
[139]. However, this study did show that interactions of
cells with 70-kDa did require activated avb3 integrins
[139], and it has also been shown that in vivo,t h ep r e -
sence of pre-existing three-dimensional FN matrices also
stimulates avb3 activation to induce FN-matrix assembly
[116]. Another possible integrin-binding site is the Ile-
Gly-Asp (IGD) sequence in FNI9[140]. It has been sug-
gested that initiation of FN-matrix assembly may be a
Figure 3 Stages of fibronectin (FN)-matrix assembly: initiation,
unfolding and fibrillar assembly. (A) FN initiation involves
interactions with cell-surface receptors: (i) FNI1-5 within the 70-kDa
domain binds to cell-surface receptors possibly including integrins,
(ii) FNIII9-10 binds to integrin a5b1, (iii) integrin activation by
outside-in or inside-out signaling induces integrins to adopt a high-
affinity state and allow FN binding and (iv) FNIII12-14 binds to
heparan sulfate proteoglycans (HSPGs). (B) FN unfolding: (i) FN
binding to cell-surface receptors induces cyctoskeletal
reorganization of the actin cytoskeleton and myosin II-dependent
contractility that results in (ii) receptor clustering and translation.
This causes the tethered FN molecules to become unfolded. (C)
Unfolding of FN results in the exposure of FN binding sites that
allow FN-FN intermolecular interactions to occur. The domains
important for each step are circled and denoted.
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region within FN, but may involve many different mole-
cules [125].
Other integrins may also be involved in the initiating the
assembly of specific FN isoforms. In an interesting study,
which demonstrated the essential role of FNIIIA+FN in
lymphatic-valve development,a9b1 integrin was shown to
be required for the assembly of EIIIA+FN by lymphatic
endothelial cells [80]; however, this assembly mechanism
may be isoform-specific, as a separate study found that
overall FN-matrix assembly by EIIIA-FN null fibroblasts
was unaffected [119].
It is well established that an essential step in the pro-
gression of FN-matrix assembly involves a5b1i n t e g r i n
binding of the RGD loop on FNIII10 and the neighboring
PHSRN sequence in FNIII9 in the CBD of FN
[116,141-146] (Figure 3Aii). a5b1i n t e g r i nb i n d i n gt o
CBD is a high-affinity interaction (Kd = 0.2 μmol/l by
solid-phase binding) [28]. FN mutants with loss of the
RGD site or a mutation within the RGD site were found
to be unable to assemble a complex fibrillar network,
forming only linear fibrillar arrays at the periphery of
cells [12,139]. Antibodies against the RGD domain or
small RGD peptides can also inhibit FN-matrix assembly
[126,133,134,147,148]. Furthermore, FN
RGE/RGE-expres-
sing mouse embryos had normal FN distribution, and
isolated embryonic fibroblasts could assemble short,
thick, FN fibrils, confirming that FNIII10 interactions
with a5b1 are not essential for assembly initiation [126].
The interaction of integrins with FN provides ‘outside-
in’ signals [149], and induces integrin clustering in focal
adhesions [60]. Ligation of integrins can also induce
intracellular signaling and the activation of integrins to
a higher-affinity binding state by ‘inside-out’ signaling.
Phosphorylation of integrin cytoplasmic domains and
subsequent integrin activation by signaling molecules
such as talin requires myosin II-dependent cell-gener-
ated tension, which is activated by force-induced
conformational changes [60,146,150,151]. ‘Outside-in’
signals can be translated into ‘inside-out’ signals via a
feedback loop [141,149,151] to regulate adhesion-com-
plex formation, integrin affinity and FN-matrix assembly
[116,146,151] (Figure 3Aiii). ‘Inside-out’ signaling and
integrin activation and clustering may precede FN bind-
ing during embryogenesis: integrin a5b1 activation and
clustering was shown to be initiated by Eph/Ephrin sig-
naling with subsequent FN-matrix assembly [152].
Cell-surface heparan sulfate proteoglycans (HSPGs)
have also been shown to play an important role in FN-
matrix assembly (Figure 3A (iv)) [153,154]. The HepII
domain of FN (FNIII12-14) can interact with heparin
[155], and the FNIII13 module is the primary binding
site [156-158], suggesting that this FN domain is
involved in the binding of HSPGs. Syndecan-2, which is
the major syndecan of fibroblasts, has been shown to be
an important HSPG for FN fibrillogenesis during zebra-
fish development [159], and supports FN-matrix assem-
bly [160].
It should be noted that models of fibril initiation are
often elucidated from two-dimensional cellular experi-
ments, in which cells also form distinct adhesive struc-
tures. In three-dimensional cultures, cells that assemble
FN do not form distinct focal or fibrillar adhesions, but
instead form long, slender ECM attachments that con-
tain both classic focal-adhesion and fibrillar-adhesion
components: a5, paxillin, vinculin, focal-adhesion
kinase, phosphotyrosine, and activated b1[ 6 2 ] .T h e s e
FN-assembly complexes probably involve a multitude of
cell-surface receptors, HSPGs and signaling molecules
that act in concert to facilitate FN-assembly initiation
[125,161].
Fibronectin unfolding, elongation and fibril formation
Upon binding to integrins and other cell-surface recep-
tors, FN then has to be unfolded from its compact
structure into an extended structure (Figure 3B)
[3,4,121].
Table 2 Fibronectin (FN)-binding integrins
FN receptor Supports fibrillogenesis Domain References
a3b1 + 70-kDa [63,146]
a4b1 + IIICS (V) CS1 region and EIIIA [63,146]
a5b1 + FNIII9-10 (RGD) [22,60,143,144,251]
a9b1 - EIIIA [65]
a8b1 - FNIII10 (RGD) [63,64]
avb1 - FNIII10 (RGD) [63,64]
avb3 + FNIII10 (RGD) or possibly 70-kDa [139,143,144]
avb6 + FNIII10 (RGD) [63]
aIIbb3 + FNIII9-10 (RGD) [38,63,145,252]
+ = Has been reported to be involved in FN fibrillogenesis.
- = Has been reported to be involved in adhesion to FN but not fibrillogenesis.
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tension and a cytoskeletal force, which translates into a
temporal change in traction force that induces conforma-
tional changes of the cell-surface-bound FN and allows
integrin crosslinking, clustering and subsequent transloca-
tion [4,60,121,136,162-164] (Figure 3Bi). FN unfolding is
dependent on b1-FN translocation from focal contacts to
central tensin-rich fibrillar-adhesion complexes [136] (Fig-
ure 3Bii), and FN fibrils are shown to form from the con-
tinuous extension of FN molecules and their
intermolecular associations [136,148,162]. FN unfolding
exposes binding sites buried in the soluble structure to
promote the interaction of FN with other FN molecules
and ECM components [165]. Cell contractility may require
a submembranous pool of myosin II, controlled by myosin
light chain kinase via RhoA-Rho kinase II-dependent
[165-167] or RhoA-independent pathways [97,166,168].
Cells in three-dimensional microenvironments may favor
different isoforms of myosin II for generating intracellular
forces compared with cells cultured in two-dimensional
environments [169]. The transduction of intracellular
cytoskeleton-generated forces and extracellular mechanical
stresses are communicated via cell-ECM contacts, allow-
ing the cell to respond to changes in its microenvironment
[161,170,171].
During embryogenesis, an alternative mechanism for
production of intracellular tension involves the activation
of the non-canonical Wnt/PCP signaling pathway, Rho
GTPase Rac, p21 activated kinase (Pak) and cadherins,
which generate cytoskeletal tension via cell-cell adhesion.
This tension is transmitted via b1 to cell-surface-bound
FN to mediate fibril formation [172]. In support of this
process, inhibition of b1 function inhibits convergence
extension tissue morphogenesis and cadherin-mediated
cell adhesion [173]. The presence of multiple pathways to
mediate cell contractility demonstrates the importance of
this generated force in FN-matrix assembly.
FNI1-5 [58,124,174,175], FNIII1-2 [10,134,165,174,176],
FNIII4-5[177] and FNIII12-14[132] are important domains
for FN fibrillogenesis, and play a role in mediating and
regulating intermolecular FN-FN interactions [12,124]
(Figure 3C). The EIIIA or EIIIB domains can also pro-
mote FN-matrix assembly, possibly by exposing integrin-
binding sites in neighboring domains: FNIII10 (EIIIB) and
IIICS region (EIIIA) [94,178].
FN module unfolding and exposure of cryptic FN-FN
binding sites further promote FN fibrillogenesis [121].
FN linker domains and the FNIII modules possess
inherent elasticity [179-182]. Domains shown to possess
cryptic binding sites include FNIII1[183-185], FNIII1-2
[10], FNIII10[184], FNIII7 and FNIII15 [186] (Figure 3C).
A peptide sequence derived from FNIII1 (FNIII1-C) can
induce superfibronectin formation; that is, high-molecu-
lar-weight, crosslinked aggregates of FN, which resemble
cell-assembled FN fibrils [185,187], indicating how effec-
tive these cryptic binding sequences are in promoting
FN-FN interactions.
FN molecules are organized into thin fibrils of 5 nm in
diameter, formed from the overlapping and staggering of
extended FN dimers and the crosslinking of FN into stable
multimers [69]. FN fibrils then become laterally associated
into thicker fibrils of 6-22 nm in diameter [69]. Further
FN-fibril interactions allow the formation of high-molecu-
lar-weight, complex, branched, fibrillar FN matrices,
which are detergent-insoluble [122,123,129]. FN cross-
linking and multimerization may occur via a partially cryp-
tic endogenous protein disulfide isomerase activity present
in FNI12, as reported by Lagenbach et al. in RNase refold-
ing experiments [69,188]. However, there is some question
as to whether covalent disulfide crosslinking is a true phe-
nomenon; there are suggestions that FN associates via
non-covalent protein-protein interactions [189,190]. The
high-molecular-weight multimers seen in non-reduced
SDS-PAGE gels are suggested to be a mixture of other
ECM proteins such as fibrillin, which ‘block’ FN dimers
from migrating through the gel [190]. This is not unex-
pected as FN is known to interact with many different
ECM components, and these protein-protein interactions
may well attenuate its migration through SDS-PAGE gels.
Once assembled, FN fibrils are continuously polymer-
ized and remodeled within the fibrillar matrix on the
cell surface [61]. FN remodeling is a dynamic process, in
which fibrils continuously detach, contract, bend,
stretch, extend, retract and anneal to neighboring fibrils
[85,87,162,164,191,192]. In vivo, the fibrillar ECM struc-
ture is deformed by local cell migratory and protrusive
activities [76,85,192,193], and large-scale tissue motion,
particularly during embryogenesis [76,85]. This strongly
extensible behavior is due to mechanical unfolding and
refolding of FNIII modules [194].
Pre-existing three-dimensional matrices act as scaf-
folds for further FN deposition; new fibrils colocalize
with pre-existing matrix [116,193,195]. Cells cultured in
native ECM scaffolds deposit more soluble FN onto pre-
existing FN fibers, requiring lower concentrations of FN
for initiation [116,193]. New FN molecules deposited by
cells onto a mature matrix are unfolded more than cells
cultured on ‘soft’ polyacrylamide substrates [195]. ECM
crosslinking has also been shown to increase the rate of
de novo FN stretching by cells but to reduce overall
deposition of soluble FN molecules [193,195], suggesting
that ECM maturation is a mechanism that regulates the
rate of FN deposition.
Fibronectin and aberrant wound-healing conditions
FN-matrix assembly has to be tightly regulated. Cellular
FN homeostasis is maintained by continual FN assembly
and loss from the pericellular matrix [61]. Persistently
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nals, and strong cell-ECM adhesions. Conversely, loss of
FN-matrix assembly is observed in some transformed
cells [168,196], and may be important during cell-migra-
tion events such as metastasis. In addition, loss of FN
deposition [61,72] would accentuate the loss in the
assembly of other ECM components within the wound
bed, as seen in chronic non-healing wounds, even
though FN expression persists and is actually increased
in the surrounding dermis [197,198].
Fibronectin in fibrotic conditions
FN plays an important role in the development of fibrotic
disease [27]. Fibrosis is characterized by an excessive
deposition of connective tissue that leads to the impair-
ment of organ structure or function, and is considered a
chronic inflammatory tissue-repair response, similar in
structure and composition to granulation tissue [199,200].
In fibrosis, there is a key interplay between the immune
response, fibroblastic-cell response and ECM, which
results in the formation of fibrotic lesions.
Although collagen is the most predominant ECM com-
ponent of fibrotic tissue, excessive deposition of FN also
occurs, and precedes the collagen deposition (Table 1)
[201-208]. In glomerular and interstitial fibrosis, there is
markedly increased expression of total FN levels, with
increased levels of EIIIA+, EIIIB+ and oncofetal (IIICS+)
isoforms detected in distinct areas of the kidney and in
areas of fibrosis [26,202-204]. Fibrogenesis is driven by
fibroblasts and myofibroblasts, which show increased
migration, proliferation, ECM synthesis and assembly
within affected tissues [114,199,209]. The presence of both
alternatively spliced EIIIA+FN and pro-inflammatory cyto-
kines such as TGF-b1 have been shown to be required in
the differentiation or transdifferentiation of cells to myofi-
broblasts [210]. For example, experiments with EIIIA null
mice suggest that EIIIA+ isoform of FN induces a-
smooth-muscle actin myofibroblast differentiation in the
presence of TGF-b1. In the absence of EIIIA+ FN, there is
continuous interstitial fibrosis after bleomycin treatment,
but no switch to a chronic fibrotic response mediated by
myofibroblasts. Furthermore, these experiments also
showed that EIIIA+FN is required for latent TGF-b1 acti-
vation, and plays a response in fibroblast response to
TGF-b1 [201,211]. TGF-b1a n dt h eT G F - b family have
been shown to activate the Smad family of transcription
factors (including Smad3), which are involved in the
expression of profibrotic genes [212]. Furthermore, mouse
models of atherosclerosis have shown the essential role of
FN in initima-media thickening in vivo [68]. Using a 49-
residue sequence from the FUD domain of the F1 adhesin
protein produced by Streptococcus pyogenes (pUR4), which
has been shown to inhibit FN-matrix assembly by binding
to the N-terminal 70-kDa domain of FN [213], this study
demonstrated that inhibiting FN-matrix assembly in vivo
significantly reduced intimal, medial and adventitial thick-
ening, collagen deposition, cell proliferation, and inflam-
matory-cell infiltration after induction of atherosclerosis
[68]. The results confirm the essential role FN plays in
mediating ECM deposition and inflammatory response,
which are corollaries of fibrosis. This study also showed
promise for possible in vivo applications for inhibiting FN
assembly.
Recently clinical studies have shown that use of a 585
nm flashlamp-pumped pulsed-dye laser resulted in the
regression or arrest of keloid development by reducing
the expression of TGF-b1in keloid tissues and increasing
the expression of matrix metalloproteinase (MMP)-13
(also called collagenase-3) [214]. As many fibrotic condi-
tions are largely untreatable, it is imperative that the
mechanisms involved in the development and mainte-
nance of these diseases are understood so that effective
therapies can be developed.
Regulation of fibronectin-matrix assembly
FN expression and assembly is stimulated in a cell-specific
manner by a multitude of molecules (Table 3). Stimulation
of FN expression, secretion and assembly by these agents
emphasizes the complexity and requirement for tight reg-
ulation of this process. As mentioned earlier, TGF-b1 and
connective tissue growth factor are key cytokines involved
in upregulating FN expression during fibrogenesis
[212,215,216]. FN deposition also requires RhoA-mediated
cell contractility [4,121,165-167] (Table 3). FN can also be
Table 3 Regulators of fibronectin (FN) mRNA expression
and assembly
References
Positive regulators of FN mRNA
TGF-b1 and the TGF-b family [212,253-255]
Platelet-derived growth factor-BB [256]
Insulin-like growth factor-1 [256]
Hepatocyte growth factor [257]
Glucose [258,259]
Glucocorticoids [260]
Negative regulators of FN mRNA
Cell contractility inhibitor [3,121]
RhoA inhibitors [165-167]
Positive regulators of FN assembly
Sphingosine-1-phosphate [261]
Estrogen [262]
Plasminogen activator inhibitor type I [263,264]
Urokinase plasminogen receptor [265]
Connective tissue growth factor [266]
Lipoprotein A [165,167]
TGF = transforming growth factor.
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FN fragments and modules can also inhibit FN-matrix
assembly by competing for FN-assembly sites [187], which
could act as a feedback system to regulate FN levels on
the cell surface. The increased levels of proteases such as
neutrophil elastase in chronic wound exudate, which can
act to degrade FN [218-222], could further contribute to
this condition. Aged clots in chronic wounds contain
highly crosslinked fibrin, which is stripped of other func-
tional proteins by the strongly proteolytic environment
[223]. These examples illustrate the importance of FN and
its assembly in regulating and resolving wound-healing
processes to maintain tissue architecture.
FN fibrils are continuously remodeled and turned over,
which is mediated via a b1-dependent, caveolin-1-depen-
dent and low-density lipoprotein receptor-related protein
(LRP)-independent endocytic mechanism [85,224]. FN
becomes targeted to the lysosomes and degraded intracel-
lularly [61,88]. As FN is assembled into high-molecular-
weight multimers by an endogenous disulfide isomerase
activity [188], some reverse proteolytic activity must occur
to allow FN endocytosis [61,88]. Furthermore, b1 integrin
clustering can induce polarized expression of membrane
type 1 (MT1)-MMP to invasive structures to cause loca-
lized ECM degradation [225]. Indeed, endocytosis of fibril-
lar FN from pre-assembled matrices was shown to be
much slower than endocytosis of soluble FN [224]. Inter-
estingly, mature FN matrices are as highly dynamic as
immature FN matrices, but ECM maturation has been
reported to assemble less dynamic ECM networks over
time, which loses this dynamic remodeling [85].
Other ECM components can also influence FN-matrix
assembly. Low levels of vitronectin (VN) have been shown
to enhance FN-matrix assembly by increasing the expres-
sion of matrix-assembly sites on the cell surface [136,226].
However, high concentrations of VN are inhibitory for
FN-matrix assembly [226-228]. The HepII domain of VN
has been shown to interact with avb3 and avb5 integrins,
preventing actin microfilament reorganization and causing
loss of FN-matrix assembly sites [228]. Loss of collagen
type VI also impairs complex FN-matrix assembly; FN
fibrils become oriented parallel to the long axis of the cell
[229]. As discussed earlier, the individual FN domains
including 70-kDa can also inhibit FN-matrix assembly by
interfering with fibril formation by the full-length
molecules.
Work carried out in our laboratory has also shown that
smaller domains of TN-C, but not the full-length protein,
can inhibit FN-matrix assembly [230,231]. As TN-C is
only coexpressed with FN in areas of physiological and
pathological tissue remodeling and the presence of
encrypted inhibitory activity within the individual TN-C
domains suggests TN-C may also play an important role
in regulating FN-matrix assembly. This highlights how
ECM composition and the breakdown of ECM compo-
nents can also act as a further level of control, which
could be exploited to control pathological wound-healing
events.
Future perspectives
Current therapies used to treat fibrotic conditions are
well summarized and discussed elsewhere [232-234]. It is
now appreciated that fibrosis can be considered an aber-
rant wound-healing response as the understanding of the
mechanism of its development is better understood
[234]. For example, anti-TGF-b has been successfully
shown to reduce skin and pulmonary fibrosis in mice
with sclerodermatous graft-versus-host disease, a mouse
model of the systemic fibrotic condition scleroderma
[235]. However, anti-TGF-b therapy has not been as suc-
cessful in human systemic sclerosis (SSc): in a placebo-
controlled phase I/II trial, systemic and repeated dosing
of CAT-192, an antibody developed against active TGF-
b1, showed no efficacy in a cohort of 45 patients with
early-stage diffuse cutaneous SSc [236]. That study also
had higher mortality rates than shown in trials of other
drugs to treat diffuse cutaneous SSc, although whether
this is due to other factors was not clear [236]. The lack
of success might also have been due to the fact that other
TGF-b isoforms have profibrotic effects [212], highlight-
ing the complex interplay between the immune system,
the ECM and cell signaling during wound healing and
aberrant wounding responses. The interplay between
cells and the ECM in the regulation of homeostasis and
response to physiological and pathological events is com-
plex, and it will be vital to understand these in order to
develop therapies that can modify these processes.
Further research into the mechanisms that regulate
FN-matrix assembly will help us understand how we can
regulate it to prevent aberrant deposition that contributes
to pathological conditions. In particular, the effect of
other ECM proteins on the FN-assembly process may
comprise a regulatory mechanism that could be further
explored and exploited therapeutically. For example,
ECM proteins such as TN-C are re-expressed only in tis-
sues undergoing active remodeling, such as in fibrotic
lesions. However, the role of these molecules in fibrotic
tissues and their effects on FN expression, deposition or
assembly are still unclear. Elucidation of the complex
interplay between resident ECM constituents is likely to
reveal how physiological, synergistic control of matrix
remodeling is mediated.
Conclusions
The plasma and cellular forms of FN play temporally and
spatially distinct and vital roles during the progression of
wound healing. Plasma FN circulates in the blood plasma
in an inactive form, and is stored in the a-granules of
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mulation of the coagulation cascade. Plasma FN is then
deposited and crosslinked to the provisional FN-rich
matrix, and functions to stimulate platelet adhesion and
aggregation, and fibroblast spreading and invasion into
the clot. Cellular FN is then synthesized by the migrated
cells within the clot, and assembled into a complex, fibril-
lar matrix on the cell surface, which directs the deposi-
tion of other ECM proteins and the migration, adhesion
and differentiation of fibroblasts. Many mechanisms are
involved to regulate FN-matrix assembly, and there is
now also growing evidence that in addition to regulation
via molecules, the ECM composition and structure itself
are also important.
As ECM assembly is such a complex process, under-
standing the mechanisms involved is vital if we are to
manipulate this process. The fact that other ECM com-
ponents can affect the deposition and assembly levels of
FN suggests further levels of control that could be
exploited in cases of dysfunctional wound-healing
events. It may be that modifying the microenvironment
by altering the expression of other ECM components
may be sufficient to induce the resolution of such aber-
rant tissue-repair processes, which can lead to condi-
tions such as fibrosis.
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